



## The Prolastin Promise: Complete support for the alpha-1 journey

Personalized alpha-1 support for you,  
backed by the expertise and  
commitment of Grifols



**GRIFOLS**

**Please see Important Safety Information on back cover and enclosed full Prescribing Information.**

With services from diagnosis to treatment,  
**We're with you throughout the alpha-1 journey**



**SCREENING IS FREE, FAST, AND EASY**



Screening your patients with chronic obstructive pulmonary disease (COPD) for alpha-1 is critical to diagnosis and ensuring patients get the care they need.<sup>1-3</sup>

**AlphaID™** is a free, fast, and easy cheek swab that screens for the 14 most prevalent genetic variants associated with alpha-1.<sup>4</sup>

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) and other major respiratory organizations **recommend alpha-1 screening for all COPD patients.**<sup>1,2,5-7</sup>

Results are accessible to you and your staff through the confidential, easy-to-use portal at [myalphaID.com](http://myalphaID.com).

**CONFIRMING DIAGNOSIS IS SIMPLE**

If your patient receives an abnormal result from screening with AlphaID, confirm their serum level and diagnosis with **AlphaID CONFIRM**, a free dry blood spot test.



**TREATING WITH PROLASTIN-C LIQUID, THE #1 PRESCRIBED ALPHA-1 THERAPY**

When your patient's diagnosis is confirmed, prescribe PROLASTIN-C LIQUID, the ready-to-infuse formulation of the #1 prescribed alpha-1 therapy for over 25 years.

**AVAILABLE EXCLUSIVELY THROUGH PROLASTIN DIRECT®**

PROLASTIN-C LIQUID is only available through the PROLASTIN DIRECT specialty pharmacy, EVERSANA. PROLASTIN DIRECT makes access easy for you and your staff. PROLASTIN DIRECT reimbursement specialists who are focused solely on alpha-1 will manage the insurance verification process and may review eligibility for financial assistance programs.



- Specialists have a **>90% success rate** obtaining patient coverage for PROLASTIN-C LIQUID<sup>8</sup>
- **Assist \$0 copay program** can provide up to \$6600 annually for eligible patients in need\*

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha<sub>1</sub>-PI products.

\*PROLASTIN DIRECT can identify patients in need of financial assistance who are eligible to enroll.  
<sup>8</sup>Two-year study comparing outcomes in a 12-month observation period with augmentation therapy alone followed by a 12-month intervention period with added disease management.<sup>9</sup>  
<sup>9</sup>Nearly all participants in the study (97%) received PROLASTIN-C.<sup>9</sup>



**CARING FOR YOUR PATIENTS IS PERSONAL TO US**

Counseling your patients and setting expectations for treatment are critical, then we will take care of the rest. Your patient coordinator will call your patient soon after enrollment in PROLASTIN DIRECT to schedule their first infusion appointment and answer any of their questions. Remind your patient to expect this telephone call.

Your patient coordinator will continue to facilitate infusions, manage coverage issues, and answer questions throughout your patient's alpha-1 journey.

All of these services are provided compliments of Grifols and are free of charge to you and your patients.

Patients have a **95.8% treatment compliance rate** when enrolled in PROLASTIN DIRECT.<sup>10</sup>



**SUPPORTING PATIENTS LEADS TO BETTER OUTCOMES**

Through PROLASTIN DIRECT, patients are automatically enrolled in a disease-management program that provides one-on-one support from a trained alpha-1 patient who understands their condition.

The disease management program has been proven to impact compliance and healthcare utilization (N=878).<sup>9†‡</sup>

**Significant improvements in compliance with therapy:**

- 10%** Increase in the use of long-term oxygen therapy ( $P < 0.01$ )
- 15%** Increase in the use of long-acting bronchodilators ( $P < 0.001$ )

**Significant improvements in health outcomes and compliance:**

- 21%** Reduction in emergency room visits ( $P = 0.02$ )
- 12%** Reduction in unscheduled physician visits ( $P = 0.03$ )
- 10%** Reduction in COPD exacerbations ( $P < 0.001$ )



Please see Important Safety Information on back cover and enclosed full Prescribing Information.



# ALPHA-1 SUPPORT AT EVERY STEP FOR YOUR PRACTICE AND YOUR PATIENTS

To get started, speak with your Grifols sales specialist.



## Important Safety Information

PROLASTIN<sup>®</sup>-C LIQUID is an alpha<sub>1</sub>-proteinase inhibitor (human) (alpha<sub>1</sub>-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha<sub>1</sub>-PI (alpha<sub>1</sub>-antitrypsin deficiency).

### Limitations of Use

- The effect of augmentation therapy with any alpha<sub>1</sub>-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha<sub>1</sub>-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
- Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
- PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha<sub>1</sub>-PI deficiency has not been established

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha<sub>1</sub>-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

**Please see enclosed full Prescribing Information.**

**References:** **1.** American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. *Am J Respir Crit Care Med.* 2003;168(7):818-900. **2.** World Health Organization.  $\alpha$ 1-antitrypsin deficiency: memorandum from a WHO meeting. *Bull World Health Organ.* 1997;75(5):397-415. **3.** Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with  $\alpha$ 1-antitrypsin deficiency between 1968 and 2003. *Chest.* 2005;128(3):1179-1186. **4.** Progenika A1AT Genotyping Test Package Insert. Progenika Biopharma. **5.** Global Initiative for Chronic Obstructive Lung Disease. *Pocket Guide to COPD Diagnosis, Management, and Prevention.* 2010:1-28. **6.** Alpha-1 antitrypsin deficiency. CHEST Foundation Web site. <https://foundation.chestnet.org/patient-education-resources/alpha-1-antitrypsin-deficiency/>. Accessed February 27, 2020. **7.** Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha1-antitrypsin deficiency in the adult. *J COPD Foundation.* 2016;3(3):668-682. **8.** Data on file, PROLASTIN DIRECT program. Grifols. **9.** Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. *COPD.* 2009;6(1):31-40. **10.** Data on file. PROLASTIN DIRECT program. Grifols. 2018.

GRIFOLS